These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12757268)

  • 1. Reference pricing for drugs: is it compatible with U.S. health care?
    Kanavos P; Reinhardt U
    Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will reference pricing address the health cost conundrum?
    Iglehart JK
    Health Aff (Millwood); 2003; 22(3):7-8. PubMed ID: 12757267
    [No Abstract]   [Full Text] [Related]  

  • 4. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dilemmas in regulation of the market for pharmaceuticals.
    Maynard A; Bloor K
    Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Government commitment and regulation of prescription drugs.
    Frank RG
    Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

  • 11. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues.
    Maclure M
    Milbank Q; 2005; 83(1):131-47. PubMed ID: 15787956
    [No Abstract]   [Full Text] [Related]  

  • 14. One pill, many prices: variation in prescription drug prices in selected government programs.
    Gencarelli DM
    Issue Brief George Wash Univ Natl Health Policy Forum; 2005 Aug; (807):1-20. PubMed ID: 16167399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H; Shrank WH
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?
    Towse A
    Health Aff (Millwood); 2003; 22(3):42-5. PubMed ID: 12757270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The state and consequences of dermatology drug prices in the United States.
    Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
    J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
    [No Abstract]   [Full Text] [Related]  

  • 18. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare prescription drugs and reform: what the new law will mean to gastroenterologists and their patients.
    Fise T
    Am J Gastroenterol; 2004 May; 99(5):775-6. PubMed ID: 15128335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.